The diagnosis of a myelodysplastic syndrome (MDS) can severely limit our therapeutic choices in managing an accompanying inflammatory arthritis. Many hematologists are concerned about the possible disruption of the cytokine milieu in MDS that the addition of a biological drug may induce, and for thi...

First, you need to understand the patient's myelodysplastic syndrome (MDS) and what treatment they require for it. MDS has a huge range of risks and severity. Once you talk to their oncologist/hematologist and determine this information, you can make a treatment plan. If they are not neutropenic and...